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The aim of this study was to compare female and male asthmatics with special emphasis on
reported adherence, anxiety, and quality of sleep.
The study included 470 subjects with current asthma from the Nordic countries, who took
part in the European Community Respiratory Health Survey (ECRHS) II. Subjects
were investigated with a structured clinical interview, including questions on the presence
of respiratory symptoms and therapy. They were also asked to fill in the self-reported Hospital
Anxiety Depression scale and the Basic Nordic Sleep Questionnaire.
Inhaled corticosteroids (ORZ 0.55) and a doctor’s appointment in the last 12 months
(ORZ 0.54) implied a significantly reduced risk for non-adherence in normal situations. At
exacerbation in asthma, women had a significantly decreased risk for non-adherence
(ORZ 0.46). Female gender and anxiety were independent risk factors for both insomnia
(ORZ 3.67 and 2.53, respectively) and daytime sleepiness (ORZ 2.53 and 2.04,
respectively).17824.
u.se (R. Sundberg).
9 Elsevier Ltd. All rights reserved.
338 R. Sundberg et al.Women with asthma have a more positive attitude towards their medication, have a higher
reported adherence, and use inhaled corticosteroids more often than men. At the same time
women report more often anxiety and insomnia than men. Awareness of sex differences in
the manifestations and attitudes towards treatment of asthma is important in order to
improve asthma management.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
In early childhood, asthma is more common among males,
but after puberty the incidence increases in females1e3 and
decreases in males.4 In addition, asthma after childhood is
more severe in females than in males, and is more
frequently under-diagnosed and undertreated in females.5
In general, there is a large sex difference among adults
presenting to emergency departments with acute asthma.6
The female majority present with specific and important
pathophysiological features; however the observed differ-
ences may also represent sex differences in use of health
care.6 Several studies suggest that men and women respond
differently to their asthma disease, and that gender
differences in various measures of asthma such as symp-
toms, hospital admissions, and quality of life may be
explained by this response to disease, rather than to real
differences in disease characteristics between men and
women.1e8
Patients with chronic diseases are in general more at risk
for mental disorder.9 Feldman et al. found that mood and
anxiety disorder were the most common psychiatric diag-
noses in a patient sample of 85 adult asthma patients.
However, patients with and without mental disorders did
not differ with regard to asthma severity10. Feldman et al.
concluded in another study of 21 asthma patients with
panic disorder and 27 asthma patients without that the
initial treatment goal should be to distinguish between
anxiety mobilizing appropriate asthma self-management
versus panic anxiety that is often mistaken as an asthma
exacerbation11.
Depression among those with asthma is associated with
poor adherence to medication regimens, more severe
asthma, and poorer disease outcomes12,13. Cluley et al.
showed that the highest psychiatric morbidity was found
among those asthma patients who were poorly controlled,
were less adherent to their medication, and more
frequently dropped out from clinic visits.14
The presence of psychological problems along with
attitudes, feelings and beliefs about asthma and its treat-
ment may affect patient behavior. Characteristics which
adversely affect self-care, including compliance with
treatment, should be identified and addressed so that
morbidity due to asthma can be reduced.15 The literature
contains particularly strong evidence regarding the effects
of anxiety on asthma. Along with the heightened preva-
lence rates of anxiety disorders, in particular panic
disorder, this points to the important role of psychopa-
thology in asthma.16
The aim of this study was to compare female and male
subjects with asthma with special emphasis on reported
adherence, anxiety, and quality of sleep.Methods
Study design
The first European Community Respiratory Health Survey
(ECRHS I) documented treatment and self-reported adher-
ence,17,18 while in the follow-up study (ECRHS II) gave the
opportunity to study the factors affecting adherence to
asthma treatment.
ECRHS I19 was a multicentre study on the prevalence,
determinants, and management of asthma performed in 48
study centres during 1991e1993. ECRHS II20 was a follow-up
study, performed between 1999 and 2002, of the partici-
pants in the second stage of ECRHS. The following analyses
include data from Sweden, Iceland, and Norway covering
470 subjects with current asthma in the ECRHS II.
Ethics approval
Local ethics committees at each centre approved the study
protocols.
Questionnaires
Each participant underwent a structured clinical interview
including questions on the presence of asthma, respiratory
symptoms, and therapy. The full questionnaire can be
found at www.ecrhs.org/quests. Participants were also
asked to fill in the self-reported Hospital Anxiety Depres-
sion (HAD) scale21 and the Basic Nordic Sleep Questionnaire
(BNSQ) on sleep disturbances.22 The HAD questionnaire
consists of 14 questions 7 related to anxiety and 7 related
to depression. Each item is rated on a 4-pointscale: 0, not
at all: 1, sometimes: 2, often: 3, all the time, giving
maximum subscale scores of 21 for anxiety and depression,
respectively. The participants were asked to describe their
feelings during the last week. In the validation of the
questionnaire, a score of 0e7 in the two subscales has been
found to discriminate non cases, from doubtful cases with
a score of 8e10 and scores of 11 or more for definite cases
of anxiety and depression, respectively.21 There is also
a third cutoff of 14/15 for severe disorder.23 The HAD
questionnaire gives clinically meaningful results as
a psychological screening tool, in clinical group compari-
sons and correlation studies with several aspects of disease
and quality of life.24 The questionnaire was found to
perform well in assessing the symptom severity and case-
ness of anxiety disorders and depression in both somatic,
psychiatric and primary care patients and in the general
population.25 The seven questions on sleep disorders were
derived from the Basic Nordic Sleep Questionnaire and had
Table 1 Definition of asthma control.30,31
Asthma was considered controlled if all the following
features were present:
asthmasymptoms less than once a week
no astma attacks in the last 3 months
no activity limitations in the last 12 months
no nocturnal symptoms in the last 3 months
short-acting beta-
2agonists twice or
less per week
in the last 3 months
no use of oral steroids in the last 12 months
FEV1 of 80 % of
predicted value
or greater
Asthma was considered partly controlled if
1 or 2of the above features were absent
Asthma was considered uncontrolled if more
than 2 features
were absent or:
if asthma, shortness
of breath, or wheezing
had caused hospital/
emergency department
admission
in the last 12 months
oral steroids were used in the last 12 months
more than 12 asthma attacks in the last 3 months
Asthma in men and women 339been used previously in the Respiratory Health in Northern
Europe (RHINE) study.26 Participants were asked to esti-
mate the frequency of different symptoms during the last
months on a five point scale: 1, never; 2, less than once
a week; 3, 1e2 nights per week; 4, 3e5 nights per week;
and 5, almost every night.
Definitions
Asthma-related variables
Physician-diagnosed asthma was defined as a positive
answer to both of the questions ’’Have you ever had
asthma?’’ and ‘‘Was this confirmed by a doctor?’’27 Asthma-
related symptoms were classified as wheezing, nocturnal
chest tightness, and attacks of breathlessness following
activity, at rest or at night during the previous 12 months.
Symptomatic asthma was defined as physician-diagnosed
asthma and asthma-related symptoms or attacks of asthma
in the previous 12 months.28 Age of asthma onset was
estimated from the answer to the question: ‘‘How old were
you when you had your first attack of asthma?’’
Blood samples were collected for measurement of total
and specific serum IgE using the Pharmacia CAP System
(Pharmacia Diagnostics, Uppsala, Sweden). Specific IgE was
measured against Dermatophagoides pteronyssinus, cat,
timothy grass and Cladosporium herbarum. Atopy was
defined as sensitisation to at least one of the allergens
investigated (0.35 kU/l)
Adherence
Adherence in normal situations was assessed by the ques-
tion: ‘‘When you have been prescribed medicine for your
breathing, do you normally take: all the medicine, most of
the medicine, some of the medicine, or none of the medi-
cine?’’ Adherence during exacerbations was assessed by the
question: ‘‘When your breathing gets worse, and you are
prescribed medicine for your breathing, do you normally
take all of the medicine, most of the medicine, some of the
medicine or none of the medicine?’’ Patients answering ‘‘all
of the medicine’’ were defined as being adherent.18,29
The attitude to therapy was defined as a positive answer
to the questions: ’’Do you think it is bad for you to take
medicines all the time to help your breathing’’ and ‘‘Do you
think you should take as much medicines as you need to get
rid of all your breathing problems’’?18
The following adherence-related variables were consid-
ered: smoking habits, having taken inhaled corticosteroids
in the previous 12 months, having regular appointments for
asthma with a doctor or a nurse, having written instructions
from a doctor, having a personal peak expiratory flow (PEF)
meter, and having had spirometry during the previous 12
months.29
Asthma control
Table 1. Definition of asthma control30,31
Anxiety and depression
The definition of anxiety and depression was a cutoff point
of 8 for the two sub-scales.Insomnia and excessive daytime sleepiness
Three aspects of insomnia were assessed: difficulty inducing
sleep as ‘‘difficulty in falling asleep at night’’, difficulty
maintaining sleep as ‘‘waking up repeatedly during the
night’’, and early morning awakenings as ‘‘waking up too
early and having difficulty in getting to sleep again’’.
Insomnia was defined as reporting at least one of the three
aspects with a frequency of at least 3 nights a week.26
Excessive daytime sleepiness was defined as reported prob-
lems with daytime sleepiness at least 3 days/week.32
Statistical analysis
Statistical analyses were performed using the STATA 9
software (Stata Corp.,College, Station, Texas, USA). Chi-
squared tests and unpaired t-test were used to compare
characteristics between men and women. Multiple logistic
regression model was used to analyse determinants for
adherence, insomnia and daytime sleepiness. A p-value
<0.05 was considered to be statistically significant.
Results
Descriptive results
In total 40 % of the participants (nZ 189) were men and 60 %
(nZ 281) were women. There were no differences in age
and body mass index between the sexes. Men were more to
be sensitised to mite, cat, timothy and C. herbarum than
women, and also had a lower age of asthma onset (Table 2).
340 R. Sundberg et al.Women with asthma were more likely than men to be
smokers, have a PEF-meter, use inhaled corticosteroids and
have seen a doctor in the last 12 months. There was no
difference in asthma control between men and women
(Table 2).
Factors associated with adherence, insomnia
and daytime sleepiness
Women with asthma had a higher self reported adherence
and a less negative attitude towards their medication than
men (Table 3).
The results of the logistic regression analysis on risk
factors for non-adherence are summarized in Table 4.
Inhaled corticosteroids and an appointment with a doctor in
the last 12 months implied a significantly reduced risk for
non-adherence in normal situations. No significant associ-
ation was found for age, nocturnal attacks of breathless-
ness, smoking, anxiety and non-adherence in normal
situations. Women had a significantly reduced risk for non
adherence in exacerbations. Subjects with anxiety were
more likely to report being non-adherent in exacerbations
(Table 4). No significant sex difference was found in the
association between risk factors and reported non-adher-
ence (pinteraction> 0.1 for all independent variables).
In this study women had a higher prevalence of anxiety,
insomnia, and daytime sleepiness compared to men
(Fig. 1). Female gender was an independent risk factor for
insomnia and daytime sleepiness when this was analysed in
a multiple logistic model (Table 5). Older asthmatics were
more likely to report insomnia than their younger coun-
terparts. Anxiety was an independent risk factor for bothTable 2 Characteristic of patients with asthma in the Nordic c
Men (nZ
Age (year) 42.0 7
BMI 26.1 3
Age of asthma onset 17.1 1
Atopy 68.0
Dermatophagoides pteronyssinus 23.4
cat 49.4
timothy 49.4
Cladosporium herbarum 12.3
Nocturnal attacks of breathlessness 18.6
Personal peak expiratory flow meter 21.9
Smoking history
never-smokers 51.6
ex-smokers 33.5
current smokers 14.9
Inhaled corticosteroids 41.6
Seen a physician last 12 months 33.6
Regular appointments hospital doctor 4.8
Regular appointments GP 7.4
Regular appointments nurse 0
Emergency room treatment last 12 months 6.9
Asthma control
Controlled 33.5
Partly controlled 39.5
Uncontrolled 27.0insomnia and with excessive daytime sleepiness (Table 5),
No significant sex difference was found in the association
between risk factors and sleep- related variables
(pinteraction> 0.1 for all independent variables). No signifi-
cant association was found between sensitisation to aller-
gens and adherence, insomnia or daytime sleepiness.
Discussion
The main finding of this study was that in comparison to
men, women with asthma had a higher self - reported
adherence and a less negative attitude towards their
medication than men and were more likely to have used
inhaled corticosteroids and had appointments with a doctor
in the last 12 months. Women had a higher prevalence of
anxiety, insomnia, and daytime sleepiness than men. No
significant sex difference was found in asthma control.
In the present study women with asthma were more
adherent than their male counterparts in both in normal and
in exacerbation. Themain finding of ECRHS II, (the follow-up
study of the international cohort) compared to ECRSH I was
that adherence to asthma treatment remained low world-
wide; although it increased significantly in Continental and
extra-European areas, and subjects living in Nordic countries
were less likely to be compliant.29 The major predictors of
increased or persistent adherence were regular appoint-
ment with health care professionals, and positive beliefs
about medication. Adherence is a complex, multidimen-
sional, and dynamic phenomenon that is influenced by many
factors related to the patients, doctors, disease, and
therapy. To achieve optimal asthma control, it is important
to identify factors that contribute to non-adherence.33,34entres of ECHRS II (meanSD and %).
189) Women (nZ 281) p-value
.4 42.3 7.2 0.62
.2 26.7 5.7 0.23
3.7 21.9 13.3 0.0002
43.6 <0.0001
14.9 0.04
33.5 0.002
26.7 <0.0001
2.7 <0.0001
25.7 0.07
31.6 0.02
0.002
43.2
27.9
28.9
52.2 0.03
46.2 0.02
6.6 0.44
9.1 0.53
2.9 0.02
9.7 0.28
0.54
36.1
34.2
29.7
Table 3 Medication in the cohort (%).
Men (nZ 189) Women (nZ 281) p-value
Use of medication normally 0.08
all of the medicine 46.2 57.3
most of the medicine 23.4 18.1
some of the medicine 30.4 23.8
none of the medicine 0 0.8
Adherent in normal situations 46.2 57.3 0.02
Use of medication during exacerbations 0.002
all of the medicine 55.3 73.5
most of the medicine 20.0 12.6
some of the medicine 24.0 13.9
none of the medicine 0.7 0
Adherent during exacerbations 55.3 73.5 <0.0001
Medicine all the time considered harmful 48.2 35.3 0.009
Should take as much medication as
needed to get rid of all symptoms
35.6 39.5 0.43
Adherence in normal and exacerbations <0.0001
adherent only in normal situations 11.7 6.2
adherent only at exacerbations 14.0 17.7
adherent in both situations 34.5 51.2
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anxiety is higher in women than in men, and increases with
age.15,35 The opposite was found about depression in
Norway, the prevalence of depression is higher in men than
in women.36 The relationship between psychological
manifestation and respiratory symptoms is a point to
consider in the management of asthma.37 Neuman et al.
found that symptoms related to anxiety and especially
depression are important determinants for the develop-
ment of dyspnea, while there was less evidences that
dyspnea induces psychological symptoms.38 Bonala et al.
reported a positive correlation between both increased
anxiety and depression and higher dose of corticosteroids in
asthmatics.39 Depression and anxiety among people with
asthma are also associated with an increased level of
impaired health related quality of life.40
Our results are differ in some respects from those
of Lee et al. who found that female asthma patients
reported significantly greater health care utilisation, more
unscheduled office contact, more asthma control prob-
lems, and had more allergic manifestations than men.41Table 4 Independent determinants for non-adherence in norm
Non-adherence i
Women 0.64 (0.37e1.10)
Age per 10 year 0.85 (0.59e1.24)
Nocturnal attacks of breathlessness 0.92 (0.47e1.82)
Smoking history
never-smokers 1
ex-smokers 1.34 (0.72e2.49)
current smokers 1.34 (0.65e2.78)
Inhaled corticosteroids 0.55 (0.31e0.97)
Seen a physician in the last 12 months 0.54 (0.31e0.94)
Anxiety 1.17 (0.61e2.24)
a Adjusted for the variables in the table and centre.Conversely we found no sex differences in asthma control,
and atopy was more common in male asthmatics than in
female asthmatics.
In our study female asthmatics were much more likely to
have problems with insomnia and excessive daytime
sleepiness. The significance of insomnia and daytime
sleepiness should be taken into consideration in the search
for optimal asthma control. Krouse et al. concluded that
asthma is a chronic inflammatory disease that can signifi-
cantly affect the individual’s physical and psychosocial
functioning, for example in terms of daytime wakefulness
and sleep quality.42 The increased insomnia seen in adult
women may begin to manifest in early adolescence as
excessive daytime sleepiness.43 Improvement in sleep
quality has been shown to correlate with improvement in
asthma control, even in individuals without a specific
history of asthma-related nocturnal awakenings.44
To some extent the reported sex differences could be
related to differences in asthma phenotypes between men
and women. Women had a later asthma onset and were less
likely to have allergic asthma. Non-allergic asthma may beal and acute situations: adjusted OR (95% CI)a
n normal situations Non-adherence in exacerbations
0.46 (0.25e0.85)
1.00 (0.66e1.53)
0.67 (0.30e1.46)
1
1.16 (0.59e2.30)
1.37 (0.60e3.14)
0.74 (0.40e1.38)
0.61 (0.32e1.16)
2.35 (1.18e4.69)
05
10
15
20
25
30
35
40
45
50
Anxiety Depression Insomnia Excessive daytime
sleepiness
%
Men Women
(nmen=189) (nwomen=281)
p-value: <0.0001 p-value: 0.008 p-value: 0.14 p-value: <0.0001
Figure 1 Anxiety, depression, insomnia and excessive daytime sleepiness in the study.
Table 5 Independent determinants for insomnia and excessive daytime sleepiness adjusted OR (95% CI)a
Insomnia Excessive daytime sleepiness
Women 3.67 (1.94e6.95) 2.53 (1.32e4.86)
Age per 10 year 1.62 (1.07e2.45) 0.80 (0.52e1.22)
Nocturnal attacks of breathlessness 1.85 (0.91e3.79) 1.87 (0.91e3.59)
Smoking history
never-smokers 1 1
ex-smokers 1.29 (0.66e2.52) 1.40 (0.69e2.81)
current smokers 0.97 (0.46e2.07) 1.86 (0.87e3.95)
Inhaled corticosteroids 1.43 (0.76e2.67) 0.85 (0.44e1.65)
Seen a physician in the last 12 months 1.22 (0.66e2.28) 1.08 (0.57e2.06)
Anxiety 2.53 (1.32e4.85) 2.04 (1.54e5.60)
a Adjusted for the variables in the table and study centre.
342 R. Sundberg et al.less responsive to inhaled corticosteroid treatment45 and
thus more difficult to treat.
Women with asthma have a more positive attitude
towards their medication, have a higher reported adher-
ence, and use inhaled corticosteroids more often than men.
At the same time women report more often anxiety and
insomnia than men. Awareness of sex differences in the
manifestations and attitudes towards treatment of asthma
is important in order to improve asthma management.
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